In a groundbreaking development for the healthcare industry, Empower Clinics Inc. (CSE:EPW) (PINK:EPWCF), a leading healthcare company with an emerging research and clinical trials division, is proud to announce that its subsidiary, EPW Curesearch LLC (EPWC), has been awarded its first clinical trial. These are no ordinary contracts; they come from a major European pharmaceutical company, a member of the prestigious Fortune 500 club, with a market capitalization exceeding $100 billion.

This clinical trial is a part of a large global effort focusing on Chronic Obstructive Pulmonary Disease (COPD), demonstrating the trust and vision of Empower's strategic partners. Empower Clinics has rapidly advanced into this milestone after previously revealing a multitude of study applications under consideration, covering various disease states. As a testament to the company's robust clinical trials division, Empower Clinics anticipates its second clinical trial, a Phase 3 Atherosclerotic Cardiovascular Disease study, led by another esteemed principal investigator.

According to Steven McAuley, Chairman & CEO of Empower Clinics, the pivotal contracts, study structure, and study budgets are in hand. These milestones have positioned Empower Clinics to begin patient recruitment by November 2023. The medical site and principal investigators have already received study supplies and drugs from the sponsor, marking an exciting new chapter in the company's history.

Empower Clinics' patient recruitment strategies are designed for substantial participation. Preliminary recruitment targets will mainly consist of patients from their existing roster. The recruitment window is set to stay open through mid-2024, offering extensions as required, with each patient's involvement spanning 52 weeks, followed by an additional 20 weeks for follow-up. The sponsor has removed any limitations on maximum allowable patients, enabling Empower Clinics to source patients from multiple channels, including other medical centers and social media recruitment platforms.

Regarding the current Cease Trade Order affecting the company, various audit and accounting procedures are ongoing. Empower Clinics is navigating this process with transparency and commitment, aiming to provide updates as the situation unfolds.

Emphasizing the company's commitment to expansion, McAuley stated, "We continue to look for other medical groups and PI partnerships in other markets. We are leveraging key local relationships in markets that are large, diverse, and offer significant growth opportunities."

Empower Clinics is primed to seize a substantial market opportunity. The Clinical Research Organization (CRO) services market is on a trajectory of remarkable growth, with the global revenue projected to reach $127.3 billion by 2028, according to MarketsandMarkets. This upswing is driven by burgeoning pharmaceutical, biotechnology, and medical device R&D pipelines, along with technological advancements in clinical trials.

As Empower Clinics continues its journey, it remains steadfast in its mission to positively impact lives and future healthcare outcomes through clinical trials. The company is well-positioned to shape the future of healthcare with its dynamic approach and expanding clinical trials portfolio.

Read release: https://webfiles.thecse.com/EPW_-_PR_Clinical_Trial_10_23_2023.pdf?poYGdqW5S9bzFuWsoLIlDmiIZJLoTL2Z